Scientists have discovered vital clues to help predict, more than a decade in advance, which men may develop prostate cancer.
An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based ...
A study of 302 patients found prostate artery embolization significantly improved urinary symptoms, objective parameters, and ...
A new ASTRO clinical guideline recommends moderately shortened radiation schedules for all risk groups of localized prostate ...
Low testosterone was associated with a higher hazard of Grade Group 3 or higher prostate cancer progression in men undergoing ...
An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based ...
The update replaces ASTRO’s 2018 recommendations to reflect the growing body of evidence showing that hypofractionated ...
An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based ...
Cystitis is commonly known as a disease that primarily affects women. But cases among men have recently been increasing, ...
(n=6) remain disease-free more than two years after treatment 80% of patients treated with SYNC-T Therapy SV-102 (n=15) alive ...
It’s true. As of last Saturday, October 24, there is a new once-daily prostate cancer drug that can reduce or eliminate prostate tumors, according to Johnson & Johnson’s early-stage trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results